Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Search
Drug Profile

Vildagliptin/metformin - Novartis

Alternative Names: Equmet; Eucreas; Galvumet; Galvus Met; Galvusmet; HGP 1810; Icandra; LMF 237; Metformin/vildagliptin; Vysov M; Zomarist

Latest Information Update: 02 Jun 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; UCB
  • Class Amines; Antihyperglycaemics; Biguanides; Cycloparaffins; Insulin sensitisers; Nitriles; Polycyclic bridged compounds; Pyrrolidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 20 May 2021 The EMA approves change in label and indicates vildagliptin as an adjunct to diet and exercise in adults with Type 2 diabetes mellitus (Combination therapy) in European Union
  • 20 May 2021 The EMA approves change in label and indicates vildagliptin as an adjunct to diet and exercise in adults with Type 2 diabetes mellitus in Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain and Sweden
  • 01 Aug 2019 Vildagliptin/metformin is not yet available for Type 2 diabetes mellitus in Africa (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now